SCHEMBL18840918

SCHEMBL18840918

CN(C)c1ccc(CCCCC(c2ccc(C(F)(F)F)cc2)N2CCN(c3ccccc3)CC2)cc1

nearest known ligand 0.73

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 17/20 0.73
SIGMAR1 Q99720 1/20 0.42
MC4R P32245 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18840885 0.85 CCR3 (1.00) CCR3
SCHEMBL18844416 0.85 CCR3 (1.00) CCR3
SCHEMBL18840860 0.79 CCR3 (1.00) CCR3
SCHEMBL18840901 0.73 CCR3 (1.00) CCR3
SCHEMBL18840818 0.72 CCR3 (1.00) CCR3
SCHEMBL18840857 0.72 CCR3 (1.00) CCR3
SCHEMBL18840888 0.71 CCR3 (1.00) CCR3
SCHEMBL18840845 0.66 CCR3 (1.00) CCR3
SCHEMBL30671730 0.66 SIGMAR1 (0.73) CCR3SIGMAR1
SCHEMBL26358361 0.65 SLC6A4 (0.52) CCR3SIGMAR1MC4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170131282-A1 Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2017-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170131282-A1 Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer CCR3, CCR5, CCR1 CCR3 1/4885SIGMAR1 2400/4885MC4R 1166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.